297 related articles for article (PubMed ID: 21446888)
1. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
Lee N; Wald A
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
[TBL] [Abstract][Full Text] [Related]
2. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
Johnston JM; Shiff SJ; Quigley EM
Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
[TBL] [Abstract][Full Text] [Related]
3. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
Vazquez-Roque MI; Bouras EP
Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
Rothstein RD; Friedenberg FK
Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
[TBL] [Abstract][Full Text] [Related]
5. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
6. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Vazquez Roque M; Camilleri M
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
[TBL] [Abstract][Full Text] [Related]
7. Linaclotide: a novel approach to the treatment of irritable bowel syndrome.
Wensel TM; Luthin DR
Ann Pharmacother; 2011 Dec; 45(12):1535-43. PubMed ID: 22045908
[TBL] [Abstract][Full Text] [Related]
8. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
Love BL; Johnson A; Smith LS
Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
11. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
12. Linaclotide for constipation-predominant IBS.
Drug Ther Bull; 2013 Nov; 51(11):129-32. PubMed ID: 24227771
[TBL] [Abstract][Full Text] [Related]
13. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
14. Linaclotide in the management of gastrointestinal tract disorders.
Lacy BE; Levenick JM; Crowell MD
Drugs Today (Barc); 2012 Mar; 48(3):197-206. PubMed ID: 22462039
[TBL] [Abstract][Full Text] [Related]
15. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
[TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
[TBL] [Abstract][Full Text] [Related]
17. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
Layer P; Stanghellini V
Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
[TBL] [Abstract][Full Text] [Related]
18. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
Góngora-Benítez M; Tulla-Puche J; Albericio F
Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
[TBL] [Abstract][Full Text] [Related]
19. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
Harris LA; Crowell MD
Curr Opin Mol Ther; 2007 Aug; 9(4):403-10. PubMed ID: 17694454
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
